ScienceTech.euabout 2 hours ago
PANDA Therapeutics secures €160K for Alzheimer's therapy
2 min read
PANDA Therapeutics secured €160,000 (CHF 150,000) from Venture Kick to advance its first-in-class antibody-based Alzheimer's therapy toward clinical development. The therapy targets multiple harmful protein deposits, including amyloid-beta and tau, simultaneously. Founded by CEO Hui Zhang, the startup aims to slow disease progression more broadly than current antibody treatments.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
